EGFR and urinary bladder carcinoma: Moreover, we found that these DEAGs were also enriched in carcinogenesis and immunology, such as “HIF-1 signaling pathway”, “bladder cancer”, “platinum drug resistance”, “EGFR tyrosine kinase inhibitor resistance”, “PD-L1 expression and PD-1 checkpoint pathway in cancer”, “T cell receptor signaling pathway”, and “Th17 cell differentiation” in KEGG analysis (Figure 2(d)).